Centro De Inmunologia Molecular

Centro De Inmunologia Molecular (cim)

Cristina Maria Mateo De Acosta Del Rio

Alejandro Lopez Requena

Rolando Perez Rodriguez

Josefa Lombardero Valladares

Ernesto Moreno Frias

Yosdel Soto Lopez

Lourdes Tatiana Roque Navarro

Victor Brito Navarro

Ana Maria Vazquez Lopez

Yuniel Fernandez Marrero

Alejandro Avenida De Acosta N° 210 Lopez Requena

J Lombardero Valladares

The present invention is related to the obtaining of modified antibodies by means of DNA recombinant technology from the murine monoclonal antibody P3 (MAb P3), produced by the hybridoma cell line deposited under Budapest Treaty with accession number ECACC 94113026, and from its anti-idiotype murine monoclonal antibody 1E10(MAbai 1E10), produced by the hybridoma cell line with deposit number ECACC 97112901, with the objective of achieving monoclonal antibodies which preserve the biological function of specifically binding the antigen of the original antibodies, but being at the same time less immunogenic. The chimeric antibodies of the invention contain the variable domains of the murine immunoglobulin and the constant regions of the human immunoglobulin; and those humanized, besides containing the constant regions of the human immunoglobulins, are modified in the murine framework regions (FRs), in particular, in those zones that could be in a T cell antigenic site, so that several positions of the FRS are human as well. These antibodies can be used in the diagnosis and therapy of different types of tumors. The present invention is also related to the use of the antibodies for therapeutic and diagnostic purposes.

Ganglioside associated recombinant antibodies and the use thereof in the treatment of tumors

The present invention relates to the biotechnology and particularly with new products for use in human health. The present invention provides new specific monoclonal antibodies, which bind with high affinity sulfatides and sulfated proteoglycans. The anti sulfatides and anti sulfated proteoglycans antibodies disclosed in the present invention and described in the description, provide important diagnostic and therapeutic tools to act on pathological processes associated with the appearance of atherosclerotic plaques. Accordingly, the invention provides pharmaceutical compositions comprising MAbs of the invention or fragments thereof for the therapeutic and diagnostic use associated with cardiovascular diseases. Particularly, the present invention relates to the fragments derived from the MAbs that recognize sulfatides and sulfated proteoglycans, which can be used in the therapy or diagnosis of this pathology.

Anti sulfatides and anti sufated proteoglycans antibodies and their use

New humanized and chimeric monoclonal antibodies that recognize EGF-R and comprise an artificial sequence at least of the FRs of the heavy chain variable region of a human immunoglobulin. The hypervariable regions of both monoclonal antibodies is the following amino acid sequence: light chain:

Humanized and chimeric monoclonal antibodies that recognize epidermal

Growing community of inventors

Ciudad de la Habana, Cuba

Cristina Maria Mateo De Acosta Del Rio